833Z","dateModified":"2024-04-23T08:07:59.436Z","author":{"@type":"Person","name":"Professor Dr. Hans Lentzen","url":"https://merfi-online.com/about"},"description":"In patients with Chronic Renal Failure / Chronic Kidney Disease (CKD)\n[?id=3f4c12b4-dca6-46db-88f6-1516a395d942&linkText=Chronic+Renal+Failure+%2F+Chronic+Kidney+Disease+%28CKD%29]\nand type 2 diabetes\n[?id=faf94820-8bfe-426c-8850-c758558c19cb&linkText=type+2+diabetes], treatment\nwith finerenone resulted in lower risks of","isAccessibleForFree":false,"hasPart":[{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".tree"},{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".notes"},{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".references"},{"@type":"WebPageElement","isAccessibleForFree":false,"cssSelector":".link"}]}21:T447,

In patients with Chronic Renal Failure / Chronic Kidney Disease (CKD) and type 2 diabetes, treatment with finerenone resulted in lower risks of Chronic Renal Failure / Chronic Kidney Disease (CKD) progression and cardiovascular events than placebo.
Bakris et al. 2020 NEJM 383: 2219-2229

Finerenone & Diabetic nephropathy (DN) / diabetic kidney disease

Navigation

Contents

References (Sources)

AI Chat